Trifluridine–Tipiracil for Previously Treated Metastatic Colorectal Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

The National Institute for Health and Care Excellence (NICE) invited Servier, the company manufacturing trifluridine and tipiracil (T/T; trade name: Lonsurf(®)), to submit evidence for the clinical and cost effectiveness of T/T compared with best supportive care (BSC) for metastatic colorectal cance...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Pharmacoeconomics
Autori principali: Ramaekers, Bram L. T., Wolff, Robert, van Giessen, Anoukh, Pouwels, Xavier, Fayter, Debra, Lang, Shona, Armstrong, Nigel, Worthy, Gill, Duffy, Steven, Kleijnen, Jos, Joore, Manuela A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer International Publishing 2017
Soggetti:
Review Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5834593/
https://ncbi.nlm.nih.gov/pubmed/29177842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-017-0591-4
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi